Bristol Myers returns to Immatics for a dual-targeting cancer drug

Bristol Myers Squibb has broadened an existing partnership with German immunotherapy developer Immatics, announcing on Tuesday morning plans to acquire rights to a cancer drug nearing clinical testing.